Cantor Fitzgerald Predicts WVE FY2025 Earnings

Wave Life Sciences Ltd. (NASDAQ:WVE) – Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Wave Life Sciences in a research note issued to investors on Tuesday, April 29th. Cantor Fitzgerald analyst S. Seedhouse anticipates that the company will post earnings of ($1.09) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $10.00 target price on the stock. The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.14) per share.

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price target on shares of Wave Life Sciences in a report on Wednesday, March 26th. Wedbush began coverage on Wave Life Sciences in a research report on Tuesday, April 8th. They set an “outperform” rating and a $18.00 price target on the stock. Jefferies Financial Group started coverage on Wave Life Sciences in a research note on Tuesday, February 25th. They set a “buy” rating and a $26.00 price target for the company. Finally, StockNews.com upgraded Wave Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 8th. Two analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $21.17.

Wave Life Sciences Trading Up 2.8 %

WVE stock opened at $7.94 on Thursday. The stock has a market cap of $1.22 billion, a P/E ratio of -7.15 and a beta of -0.93. Wave Life Sciences has a 1-year low of $4.25 and a 1-year high of $16.74. The stock’s fifty day simple moving average is $8.21 and its two-hundred day simple moving average is $11.47.

Wave Life Sciences (NASDAQ:WVE) last released its quarterly earnings data on Tuesday, March 4th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.34. The business had revenue of $83.75 million for the quarter, compared to analyst estimates of $25.60 million. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%.

Institutional Investors Weigh In On Wave Life Sciences

Several large investors have recently bought and sold shares of WVE. Price T Rowe Associates Inc. MD increased its position in shares of Wave Life Sciences by 63.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,098,866 shares of the company’s stock valued at $63,074,000 after purchasing an additional 1,972,262 shares during the last quarter. Loomis Sayles & Co. L P purchased a new stake in shares of Wave Life Sciences in the fourth quarter valued at $20,545,000. Polar Capital Holdings Plc bought a new stake in shares of Wave Life Sciences in the 4th quarter worth about $12,370,000. MPM Bioimpact LLC grew its holdings in Wave Life Sciences by 138.5% during the 4th quarter. MPM Bioimpact LLC now owns 1,489,237 shares of the company’s stock valued at $18,422,000 after purchasing an additional 864,766 shares during the last quarter. Finally, Driehaus Capital Management LLC raised its position in Wave Life Sciences by 14.6% in the 4th quarter. Driehaus Capital Management LLC now owns 6,712,449 shares of the company’s stock worth $83,033,000 after purchasing an additional 853,589 shares during the period. Institutional investors own 89.73% of the company’s stock.

Insider Transactions at Wave Life Sciences

In other Wave Life Sciences news, Director Christian O. Henry sold 10,500 shares of the business’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $9.77, for a total value of $102,585.00. Following the sale, the director now owns 16,115 shares in the company, valued at $157,443.55. The trade was a 39.45 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Paul Bolno sold 169,025 shares of Wave Life Sciences stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $9.57, for a total value of $1,617,569.25. Following the completion of the sale, the chief executive officer now directly owns 338,351 shares in the company, valued at $3,238,019.07. This trade represents a 33.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 29.10% of the company’s stock.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.